Application No.: 09/886,144

Attorney Docket No.: 03528.0050.CNUS01

THE AMENDMENTS

In the Claims

1. (Previously Amended) A method for purifying and concentrating AAV-2 and antigen portions thereof from a sample, said method comprising the steps of:

binding AAV-2 or antigen portions thereof to an activated chromatographic material which comprises antibodies linked thereto and directed against AAV-2, and

eluting said AAV-2 or antigen portions thereof using a solution containing 0.5 to 4.5 2-3 M MgCl₂.

- 2. (Previously Amended) The method according to claim 1, wherein said AAV-2 is a wild-type AAV-2 or a recombinantly prepared AAV-2.
- 3. (Original) The method according to claim 1 or 2, wherein the chromatographic material is selected from the group consisting of agarose gels, dextran gels, cellulose gel matrices and acrylamide gel matrices.
- 4. (Previously Amended) The method according to claim 1 or 2, wherein the chromatographic material carries a ligand suitable for binding proteins.
- 5. (Previously Amended) The method according to claim 3, wherein the chromatographic material is CNBr-activated agarose or NHS-activated agarose.
- 6. (Cancelled).
- 7. (Previously Amended) The method according to claim 1 or 2, wherein the sample containing the AAV-2 is a cell culture supernatant or cell extracts.
- 8. (Previously Amended) The method according to claim 1 or 2, wherein the antibody directed against AAV-2 is DSM ACC2194.

Application No.: 09/886,144 Attorney Docket No.: 03528.0050.CNUS01

9. (Previously Amended) A kit for carrying out the method according to claims 1 or 2, comprising

an antibody directed against AAV-2, and conventional auxiliary agents selected from the group consisting of buffers, chromatographic material and controls.